Martin H. Cohen - Concepedia

Author

Martin H. Cohen

Also Known As

Cohen, Martin H., M Cohen, M H Cohen, M. Cohen, M. H. Cohen, M. Harry Cohen, M.H Cohen, M.H. Cohen, MARTIN COHEN, MARTIN H. COHEN

219

Publications

16.3K

Citations

H-Index

171

Concepts

All Affiliations

Center for Drug Evaluation and Research United States Food and Drug Administration United States Department of Veterans Affairs National Cancer Institute Center for Neuro-Oncology

About

Martin H. Cohen is an author at Center for Drug Evaluation and Research specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	81	8.1K
2	Health Sciences	19	24	1.8K
3	Public Health	3	3	470
4	Natural Sciences	2	2	26
5	Engineering	1	1	21

Martin H. Cohen

123

Publications

15.4K

Citations

H-Index

Page 1

	Year	Citations
Prognostic effect of weight loss prior tochemotherapy in cancer patients William D. DeWys, Colin B. Begg, Philip T. Lavin, The American Journal of Medicine ObesityOncologyBody CompositionCancer ManagementPrognosis	1980	2.3K
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma Bhupinder Mann, John R. Johnson, Martin H. Cohen, The Oncologist	2007	1.3K
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme Martin H. Cohen, Yuan Li Shen, Patricia Keegan, The Oncologist	2009	635
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara, The Oncologist Gefitinib 250OncologyCancer ManagementPharmacologyClinical Trials	2003	569
United States Food and Drug Administration Drug Approval Summary Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara, Clinical Cancer Research Gefitinib TherapyDrug PolicyCancer PharmacologyPharmacotherapyGefitinib Effectiveness	2004	500
CNS metastases in small cell bronchogenic carcinoma.Increasing frequency and changing pattern with lengthening survival John L. Nugent, Paul A. Bunn, Mary J. Matthews, Cancer	1979	483
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Martin H. Cohen, Grant Williams, John R. Johnson, PubMed	2002	469
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets Martin H. Cohen, John R. Johnson, Yeh‐Fong Chen, The Oncologist	2005	434
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease Min Lu, Martin H. Cohen, Dwaine Rieves, American Journal of Hematology Iron MetabolismIntravenous Iron TherapyDialysis TherapyPharmacotherapyOral Iron	2010	433
Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors Martin H. Cohen, Ann T. Farrell, Robert Justice, The Oncologist Surgical OncologyImatinib MesylateGastrointestinal OncologyMedicineMalignant Disease	2009	428

Page 1